Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | ESRRG | P62508 | 1/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 4/20 | 0.35 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.35 |
| ▸ | KIF11 | P52732 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | BCHE | P06276 | 1/20 | 0.34 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4575245 | 0.83 | FFAR4 (0.37) | NR1H2NR1H3KDM4ELMNAGAA | |
| SCHEMBL4575335 | 0.82 | PPARA (0.52) | — | |
| SCHEMBL4575407 | 0.81 | FFAR4 (0.33) | KDM4ELMNAGAAHTTSMN1; SMN2 | |
| SCHEMBL4574711 | 0.79 | CETP (0.43) | BCHE | |
| SCHEMBL4575880 | 0.78 | NR1H2 (0.42) | NR1H2NR1H3KDM4ELMNAGAA | |
| SCHEMBL4575469 | 0.75 | PPARD (0.48) | — | |
| SCHEMBL4576207 | 0.75 | PPARA (0.52) | — | |
| SCHEMBL2414732 | 0.73 | PPARA (0.38) | KDM4ELMNASMN1; SMN2 | |
| SCHEMBL4575464 | 0.73 | PPARA (0.54) | — | |
| SCHEMBL14277953 | 0.72 | KDM4E (0.30) | KDM4ELMNAGAAHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7319104-B2 | hPPARs activators | SMITHKLINE BEECHAM CORPORATION (US) | 2008-01-15 | — | — | US | disclosed |
| US-20050137212-A1 | Hppars activators | SMITHKLINE BEECHAM CORPORATION | 2005-06-23 | — | — | US | disclosed |
| EP-1480957-A1 | HPPARS ACTIVATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-12-01 | — | — | EP | disclosed |
| WO-2003074495-A1 | HPPARS ACTIVATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137212-A1 | Hppars activators | PPARG, PPARA, PPARD | NR1H2 5/4885NR1H3 4/4885KDM4E 4112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.